Champions oncology, INC in vivo evaluation of ncatss compound in a low passage tumorgraft model of cholangiocarcinoma

Ended Purchase Order Awarded Last action

Contract number
HHSN271201500258P
Awardee
Awarding agency
Obligated
$0

Award facts

Contract value
$0.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
NAICS code
541711 Research and Development in Biotechnology
PSC
Q301 Reference Laboratory Testing
Set-aside
Total Small Business
Competition
Competed under SAP · 3 offers Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Hackensack, NJ 07601, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 · In vivo evaluation of ncatss compound in a low passage tumorgraft model of cholangiocarcinoma -$40,500
Original award $40,500

Quick answers

Who was awarded contract HHSN271201500258P?

HHSN271201500258P was awarded to Champions Oncology, Inc. by National Institute on Drug Abuse (National Institutes of Health) on April 15, 2015.

How much is contract HHSN271201500258P worth?

The government has obligated $0 on HHSN271201500258P.

Which agency awarded contract HHSN271201500258P?

National Institute on Drug Abuse (National Institutes of Health) awarded HHSN271201500258P, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).

Was contract HHSN271201500258P competed?

The extent of competition for HHSN271201500258P was competed under sap. The government received 3 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login